There are a lot of Chinese medicine in the Chinese medicine industry that can be used for a number of public offering of ETFs of traditional Chinese medicine

Reporter Wang Siwen

In recent years, Chinese medicine -related favorable policies have been introduced, and the Chinese medicine industry has ushered in a period of development dividends. As an important part of institutional investors, many fund companies are also densely deployed Chinese medicine -themed products, especially index funds.

Regarding the reasons for actively deploying traditional Chinese medicine track -related products, a number of fund companies told the Securities Daily reporter that one is to optimize the investment value of the Chinese medicine industry, and the other is to provide convenient investment channels for ordinary investors to participate in the Chinese medicine track. Industry insiders believe that the future targets related to the traditional Chinese medicine industry will be further watched by all parties of the market.

Since June this year, the rich country, investment promotion, and Huitianfu Fund have declared the Chinese medicine ETF products that track the Chinese Medicine Index Index. Earlier, there have been Huatai Berry Fund, Penghua Fund, Yinhua Fund and other companies to declare related products. Eventually, the first batch of Chinese medicine ETF funds will be officially launched.

Talking about the reasons for the fund company's application for Chinese medicine ETF products, Xu Rongman, the manager of China Merchants State Certificate Biomedical Fund, told a reporter from the Securities Daily, "It is mainly due to the relatively scarce Chinese medicine related products on the market, and the Chinese medicine industry has different pharmaceutical subdivision competitions. The development logic of the road, etc. "

Zhang Yuxiang, the fund manager of the Penghua Fund's quantitative and derivative investment department, analyzed the reporter of the Securities Daily that "Since 2019, the state has issued many policy documents and vigorously develops the cause of Chinese medicine. The important role, the public's acceptance of Chinese medicine has also continued to improve. The national policy level promotes the strengthening of the construction of traditional Chinese medicine medical capabilities, increases talent training, and further standardizes the inheritance of Chinese medicine and innovative development, which is conducive to the overall development of the Chinese medicine industry. ","

The manager of the Hang Sea Consumption Upgrade Hybrid Fund and the chief of pharmaceutical research, Rona, also told the "Securities Daily" reporter, "Benefiting from the favorable policy, the further expansion of the Chinese medicine industry, the relevant investment value is very prominent. The main reason. "

"On the other hand, the Penghua Fund's layout of traditional Chinese medicine index products is also to facilitate investors to invest in the Chinese medicine industry." Zhang Yuxiang told reporters.

Lu Na further analyzed reporters that "if Chinese medicine ETF products are approved, they have two great benefits for investors. First, it is difficult to reduce investment in the Chinese medicine industry. The traditional Chinese medicine industry is a knowledge and technology -intensive industry, with high professionalism, industry Fast development, long industrial chain extension, and industry segmentation are more complicated. Second, decentralized investment risks. Compared with single stocks, ETF products fluctuate smaller. "

"However, the overall professionalism of the pharmaceutical industry and the rapid development of the industry, and the differentiated circuit differentiation is also obvious. When investors invest in related varieties, they need to carefully identify the specific investment direction of the product. At the same time, they can pay more attention to the industry and core "Xu Rongman told reporters.

According to the reporter's observation, in addition to the recent densely declared Chinese medicine ETF, there are two Chinese medicine theme funds in the market. Huitianfu Chinese Medicine Index LOF. The latest scale of these two funds was 1.144 billion yuan and 2.413 billion yuan, respectively, and the yields since its establishment were 120.03%and 19.48%, respectively.

Looking forward to the future development of the Chinese medicine sector, Zhang Yuxiang told the "Securities Daily" reporter, "Before that, the Chinese medicine sector experienced a period of confusion and dilemma, and it was expected to usher in reversal in 2022. In recent years Introduction; In the context of the overall pharmaceutical sector valuation callback, the traditional Chinese medicine sector as a low valuation sector is expected to usher in the valuation reshaping; it is expected that this round of traditional Chinese medicine market has medium- and long -term sustainability. Traditional Chinese medicine has consumer goods and health products attributes. At present, driven by the growth of medical and health care demand for middle -aged and elderly people, driven by factors such as the increase in the growth of health care and the upgrading of residents' consumption, the Chinese medicine industry has continued to develop, and the Chinese medicine industry in the future is very promising. "

- END -